No new safety signals were observed in the analysis.
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
References
- Janssen Pharmaceutical Companies of Johnson & Johnson. News release: New phase 3 data showed first-in-class Tremfya (guselkumab) provided durable complete skin clearance through five years in moderate to severe plaque psoriasis (PsO) and robust joint symptom improvement through 52 weeks in active psoriatic arthritis (PsA). 2021 March 16.
- McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, a monoclonal antibody specific to the p19-subunit of interleukin 23, through 2 years: Results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis [abstract]. The Innovations in Dermatology: Virtual Spring Conference. 2021 Mar 16–20.